Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Current Assets: 2022-2024

Historic Current Assets for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $562.3 million.

  • Day One Biopharmaceuticals' Current Assets fell 15.67% to $490.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $490.0 million, marking a year-over-year decrease of 15.67%. This contributed to the annual value of $562.3 million for FY2024, which is 49.85% up from last year.
  • Day One Biopharmaceuticals' Current Assets amounted to $562.3 million in FY2024, which was up 49.85% from $375.3 million recorded in FY2023.
  • Day One Biopharmaceuticals' Current Assets' 5-year high stood at $562.3 million during FY2024, with a 5-year trough of $347.9 million in FY2022.
  • Over the past 3 years, Day One Biopharmaceuticals' median Current Assets value was $375.3 million (recorded in 2023), while the average stood at $428.5 million.
  • Data for Day One Biopharmaceuticals' Current Assets shows a peak YoY spiked of 49.85% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Current Assets stood at $347.9 million in 2022, then climbed by 7.88% to $375.3 million in 2023, then soared by 49.85% to $562.3 million in 2024.